Experimental drug tarlatamab takes on rare, Tough-to-Treat cancer
Disease control
Recruiting now
This phase 2 trial is testing a drug called tarlatamab in 60 adults with advanced extrapulmonary neuroendocrine carcinoma, a rare cancer that has come back after standard chemotherapy. Tarlatamab works by helping the body's immune cells find and attack cancer cells. The main goal…
Phase: PHASE2 • Sponsor: Inkeun Park • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC